Public Procurement of Medicines in Europe: Key Findings and Best Practices
Experts in the Pharmacoeconomics Department recently conducted a study on the best practices in the public procurement of medicines. Commissioned by the European Commission, this study aims to improve access to medicines, affordability, availability, and more.
Public procurement of medicines can improve access, foster competition, and address important policy objectives. This study mapped and analyzed PPM practices across 32 European countries, revealing some fascinating insights.
Findings include:
- Different organizational forms of procurement, ranging from facility-based to centralized procurement.
- Use of various procedures and techniques, including the Most Economically Advantageous Tender
- Specific forms of procurement in the hospital sector
- Impacts on policy objectives, such as access to medicines and environmental protection
- Best practices for optimizing PPM in Europe
Discover the full report for a comprehensive understanding of PPM practices in Europe on the below link. Let’s work together to ensure affordable and accessible medicines for all!
Recent Posts
Transforming Brain Health Innovation with Patient Experience Data: Strategic Insights for Health ...
Innovative approaches to brain health increasingly recognize that patient experience data (PXD)—systematically collected information on patients’ lived experiences of interventions and disease—are crucial for aligning research, development, and regulatory decisions with real-world needs. The refe...
Comprehensive Review of Type 2 Diabetes Treatment and Diagnosis Strategies
Type 2 diabetes treatment is a complex and evolving topic, with patients and clinicians often asking: “What are the most effective and current strategies for managing adult type 2 diabetes?” In recent years, traditional medical sources highlight the importance of individualized care—blending life...
Dutch Pharmacoeconomic Redesign: Streamlined Structure and Enhanced Transparency for Drug Assessment
The recently published concept report from the Dutch National Health Care Institute (Zorginstituut Nederland) introduces a fundamentally new structure for pharmacoeconomic assessments, known as the Dutch Pharmacoeconomic Redesign, effective September 1, 2025. This revised format applies to both d...